Journal ArticleDOI
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.
Franz X. Vollenweider,Margreet F. I. Vollenweider-Scherpenhuyzen,Andreas Bäbler,Helen Vogel,Daniel Hell +4 more
Reads0
Chats0
TLDR
In healthy human volunteers, the psychotomimetic effects of psilocybin were blocked dose-dependently by the serotonin-2A antagonist ketanserin or the atypical antipsychotics risperidone, but were increased by the dopamine antagonist and typical antipsychotic haloperidol.Abstract:
Psilocybin, an indoleamine hallucinogen, produces a psychosis-like syndrome in humans that resembles first episodes of schizophrenia. In healthy human volunteers, the psychotomimetic effects of psilocybin were blocked dose-dependently by the serotonin-2A antagonist ketanserin or the atypical antipsychotic risperidone, but were increased by the dopamine antagonist and typical antipsychotic haloperidol. These data are consistent with animal studies and provide the first evidence in humans that psilocybin-induced psychosis is due to serotonin-2A receptor activation, independently of dopamine stimulation. Thus, serotonin-2A overactivity may be involved in the pathophysiology of schizophrenia and serotonin-2A antagonism may contribute to therapeutic effects of antipsychotics. Language: enread more
Citations
More filters
Journal ArticleDOI
The potential of psychedelics for the treatment of Alzheimer's disease and related dementias
Journal ArticleDOI
Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial)
Mathias E. Jensen,Dea S. Stenbæk,Tobias Søgaard Juul,Patrick M. Fisher,Claus Thorn Ekstrøm,Gitte M. Knudsen,Anders Fink-Jensen +6 more
TL;DR: In this paper , the effects of psilocybin-assisted therapy versus placebo in a randomized, double-blinded, placebo-controlled 12-week clinical trial were investigated.
Journal ArticleDOI
Molecular insights into psychedelic drug action.
TL;DR: The authors reviewed the current knowledge regarding the molecular details of psychedelic drug actions and suggest that these discoveries can facilitate new insights into their hallucinogenic and therapeutic mechanisms, which can facilitate the further development of such applications, however, is a clearer understanding of how drugs exert their effects at the molecular level.
Journal ArticleDOI
Exploring the Potential Utility of Psychedelic Therapy for Patients With Amyotrophic Lateral Sclerosis.
TL;DR: In this paper , the potential of LSD assisted psychotherapy to alleviate psychiatric and psychospiritual distress in ALS patients was examined and the safety of using LSD in this population and putative neurobiological mechanisms that may therapeutically intervene on ALS neuropathology.
References
More filters
Journal ArticleDOI
Schizophrenics show spatial working memory deficits.
Sohee Park,Philip S. Holzman +1 more
TL;DR: It is demonstrated that schizophrenics are impaired on spatial delayed-response tasks, analogous to those that have been used to assess the working memory function of the dorsolateral prefrontal cortex in rhesus monkeys, and that this deficit is modality independent.
Journal ArticleDOI
The Mechanism of Action of Novel Antipsychotic Drugs
TL;DR: The chief evidence for this position is that clozapine (CLOZ) does not differ from typical antipsychotic drugs in these regards but is more effective than typical neuroleptic drugs.
Journal ArticleDOI
Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens
TL;DR: Results indicate that an important component of the mechanism of action of LSD and the phenylisopropylamine hallucinogens is through stimulation of brain 5-HT2 receptors, and supports previous suggestions to this effect.
Journal ArticleDOI
Alterations in the cortical serotonergic system in schizophrenia: A postmortem study
TL;DR: In this paper, the authors characterized various components of the 5-HT system in 14 areas of the frontal and parietal cortex in tissue obtained at postmortem from aged chronically hospitalized nonsuicidal schizophrenics compared to age-matched controls.
Journal ArticleDOI
5-HT receptors: subtypes and second messengers.
Daniel Hoyer,Philippe Schoeffter +1 more
TL;DR: Three main families of 5-HT receptors, of which subtypes have been described, are now accepted, and heterogeneity is further substantiated by the cloning of the cDNA's of three different 5- HT receptors.